You just read:

OncoQuest to Present Oregovomab Phase II Interim Clinical Results for Front Line Treatment of Ovarian Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting

News provided by

OncoQuest Inc.

May 24, 2017, 09:30 ET